Crossmark

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Crossref DOI link: https://doi.org/10.1186/s12885-018-4331-8

Published Online: 2018-05-04

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Penault-Llorca, Frédérique https://orcid.org/0000-0002-4279-5492
Filleron, Thomas

Asselain, Bernard

Baehner, Frederick L.

Fumoleau, Pierre

Lacroix-Triki, Magali

Anderson, Joseph M.

Yoshizawa, Carl

Cherbavaz, Diana B.

Shak, Steven

Roca, Lise

Sagan, Christine

Lemonnier, Jérôme

Martin, Anne-Laure

Roché, Henri
Funding

Funding for this research was provided by:

Genomic Health
License Information

Text and Data Mining valid from 2018-05-04
More Information

Article History

Received: 26 September 2016

Accepted: 4 April 2018

First Online: 4 May 2018

Ethics approval and consent to participate

: The PACS-01 protocol was reviewed and approved by the French Ethics Committee/Institutional Review Board (CCPPRB of Toulouse, France). Written informed consent was obtained before randomization. The informed consent of the parent PACS-01 trial mentioned that tumoral tissues could be prospectively analyzed for research purpose.

: FLB, JMA, CY, DBC and SS are employees of Genomic Health, Inc. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below